ArticleFrontiers in oncology2025
Bibliometric analysis of rhein in the treatment of tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Application of artificial intelligence in palliative care: a bibliometric analysis of research hotspots and trends.Frontiers in medicine · 2025Pooled it
- Rhein and its derivatives: potential anti-tumor drugs and corresponding targeted mechanism.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rhein is an anthraquinone compound with a variety of biological activities. It has inhibitory effects on liver cancer, breast cancer, lung cancer, oral cancer, gastric cancer, and other cancers. However, a comprehensive bibliometric review of this field has not yet been published. Objective: This study aims to investigate and evaluate the current research trends and directions about the antitumor properties of rhein using bibliometric analysis. Methods: The literature related to rhein in cancer treatment from 2003 to 2023 was retrieved from the Web of Science Core Collection (WoSCC) database, and the annual number of publications, main authors, major institutions, keyword clustering, and keyword bursts were visually analyzed using CiteSpace 6.3.R1 software. This study aims to discuss the status quo, hotspots, and development trends of rhein research over the past 20 years. Results: A total of 220 articles were retrieved from the core collection database, and the number of articles related to treating tumors with rhein increased annually. Among them, Chung, Jing Gung has the highest number of articles in this field, but most researchers lack cooperation with each other. The institutions with the highest number of articles were the Nanjing University of Chinese Medicine (13 articles) and China Medical University (Taiwan) (13 articles). Research hotspots include the promotion of apoptosis, endoplasmic reticulum stress, inhibition of proliferation, drug resistance, and nanoparticles. Conclusion: Rhein exerts antitumor effects by inducing cell apoptosis, controlling metastasis, and inhibiting proliferation. However, owing to its poor water solubility, in recent years, functional modification of its functional groups or production of rhein nanoparticles to enhance its bioavailability and antitumor effects has become a hot research direction in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.